nRBC is being developed to treat traumatic brain injury complicated with hypotension as an orphan indication.
Traumatic brain injury (TBI) is a leading cause of morbidity and mortality in both civilian and military settings. Secondary insults, such as hemorrhagic shock (HS), are common and have a devastating impact on outcome.
nRBC is specifically designed to meet un-met critical care needs where there is inadequate blood flow and insufficient oxygen delivery. In cases of TBI+HS, nRBC can stabilize hemodynamics to increase oxygen delivery to the brain without increasing intracranial pressure (ICP) and brain edema while protecting the brain cells from other secondary damage.